First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication
Takeda press release announcement detailing clinical trial results for ENTYVIO in treating ulcerative colitis.
Top header with logo and tagline, followed by a split banner with press release title and lab imagery. Content block features news headline, date, CTA link, followed by an alert rating survey and informational footer.
Color palette
Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.
More emails like this
Explore other emails with shared design, campaign, or industry tags.
